Optimizing Therapies Using Therapeutic Drug Monitoring: Current Strategies and Future Perspectives

Peter M. Irving*, Krisztina B. Gecse

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

32 Citations (Scopus)

Abstract

Therapeutic drug monitoring (TDM) has emerged as a strategy for treatment optimization in inflammatory bowel diseases to maximize benefit and to reach more stringent, objective end points. Optimal drug concentrations in inflammatory bowel disease vary according to treatment target, disease phenotype, inflammatory burden, and timing of sampling during the treatment cycle. This review provides an update on TDM with biologic and oral small molecules, evaluates the role of reactive vs proactive TDM, and identifies the gaps in current evidence. In the future, adaptations to how we use TDM may contribute further to the goal of personalized treatment in patients with IBD.

Original languageEnglish
Pages (from-to)1512-1524
Number of pages13
JournalGastroenterology
Volume162
Issue number5
DOIs
Publication statusPublished - Apr 2022

Keywords

  • Crohn's Disease
  • Inflammatory Bowel Diseases
  • Therapeutic Drug Monitoring
  • Ulcerative Colitis

Fingerprint

Dive into the research topics of 'Optimizing Therapies Using Therapeutic Drug Monitoring: Current Strategies and Future Perspectives'. Together they form a unique fingerprint.

Cite this